Robert Benjamin Stein M.D., Ph.D.
Net Worth
Last updated:
What is Robert Benjamin Stein M.D., Ph.D. net worth?
The estimated net worth of Dr. Robert Benjamin Stein M.D., Ph.D. is at least $6,533,040 as of 16 May 2023. He owns shares worth $2,256,401 as insider, has earned $907,119 from insider trading and has received compensation worth at least $3,369,520 in MiMedx Group, Inc..
What is the salary of Robert Benjamin Stein M.D., Ph.D.?
Dr. Robert Benjamin Stein M.D., Ph.D. salary is $842,380 per year as Executive Vice President of R&D in MiMedx Group, Inc..
How old is Robert Benjamin Stein M.D., Ph.D.?
Dr. Robert Benjamin Stein M.D., Ph.D. is 74 years old, born in 1951.
What stocks does Robert Benjamin Stein M.D., Ph.D. currently own?
As insider, Dr. Robert Benjamin Stein M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | Executive Vice President of R&D | 317,803 | $7.1 | $2,256,401 |
What does MiMedx Group, Inc. do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Robert Benjamin Stein M.D., Ph.D. insider trading
MiMedx Group, Inc.
Dr. Robert Benjamin Stein M.D., Ph.D. has made 14 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 10,365 units of MDXG stock worth $61,630 on 16 May 2023.
The largest trade he's ever made was exercising 51,756 units of MDXG stock on 4 May 2023. As of 16 May 2023 he still owns at least 317,803 units of MDXG stock.
MiMedx Group key executives
MiMedx Group, Inc. executives and other stock owners filed with the SEC:
- Dr. Robert Benjamin Stein M.D., Ph.D. (74) Executive Vice President of R&D
- Dr. Rohit Kashyap Ph.D. (54) Executive Vice President & Chief Commercial Officer
- Mr. Peter Martin Carlson CPA (61) Chief Financial Officer
- Mr. Timothy R. Wright (67) Chief Executive Officer & Director
- Mr. William F. Hulse IV (51) Gen. Counsel & Sec.